- | Revolo Biotherapeutics
Restoring Balance to the Immune System in Allergic Diseases
Revolo Biotherapeutics is developing a synthetic peptide therapy that can potentially restore immune system homeostasis in EOE and other allergic diseases.
- | MeiraGTx
This Founder’s Gene Therapy Company Helped Blind Kids See Again
Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders. Now it’s on the cusp of its first regulatory approval.
- | COUR Pharmaceuticals
Tolerogenic Therapies Retrain the Immune System
COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases
- | LB Pharmaceuticals
A CEO With A General Counsel’s Perspective
With LB Pharmaceuticals, Turner “liked the fact that it’s a very focused neuropsych company; this is where we’re going. And I also liked the fact that there was a near-term catalyst with our Phase 2 clinical program.” In other words, the company had a clear strategy in place; all it needed was a leader who could execute effectively.
- | Tessera Therapeutics
Tessera Therapeutics Advances In Vivo Gene Therapy For SCD
Last year, Tessera Therapeutics’ CEO, Dr. Michael Severino, was my guest on Cell & Gene: The Podcast to discuss Gene Writing, the biotech’s genome
- | COUR Pharmaceuticals
Chicago Area’s Life Sciences Scene Continues Making an Impression
Chicago Biomedical Consortium and COUR Pharmaceuticals executives share what makes the area a hot spot.
- | LB Pharmaceuticals
With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding
A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start a …
- | LB Pharmaceuticals
LB Pharma’s twist on old Sanofi drug passes schizophrenia test, teeing up phase 3 push
LB Pharmaceuticals has shared top-line data from a phase 2 schizophrenia trial, touting results that offer early support for its vision and putting it on track to start a pivotal study around the end of the year.
